Colon Cancer

Erbitux testing resumes

Published in Medical Letter on the CDC and FDA, November 24th, 2002

ImClone Systems, Inc., and Bristol-Myers Squibb, Inc., are beginning a new round of clinical tests of Erbitux, a promising drug to treat colon cancer.

A 250-patient phase II trial is now under way that the companies hope ultimately will pave the way to a U.S. Food and Drug Administration approval, ImClone and Bristol said October 4, 2002. Larger trials are scheduled to begin next year.

The companies' application for approval to market the drug, which has shown promise in treating colon cancer without the side effects of chemotherapy, was rejected by regulators last December for scientific flaws in the clinical studies.

Since...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2002-11-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry